WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Azelon Pharmaceuticals, Inc., a biopharmaceutical company developing treatments for osteoporosis, announces the completion of a phase 2a trial comparing nasal spray ZT-034 to Forteo administered by subcutaneous injection and placebo in women with low bone mass. Following data collection and analysis, the clinical results are expected in July.
